Genmab遭降評級:專利到期陰影,股價恐承壓?

Bernstein睇淡Genmab前景,專利藥到期、收購成疑。收入大跌預期下,目標價插水式下調。Genmab仲有無翻身機會,定係蟹硬呢?
Read More